Back to search results

Study of BMS-986533 in Healthy Volunteers

This study is looking for healthy volunteers aged 18 to 55 years old to test a drug called BMS-986533. The main goals are to understand how safe BMS-986533 is and how your body handles it (pharmacokinetics) when given in single or multiple doses. Researchers will also see how food and stomach acid (pH) affect the drug, and if it interacts with other common medications like Famotidine, Dabigatran Etexilate, or Rosuvastatin. Success for this study means understanding the safety of BMS-986533 and how it works in the body. The study plans to enroll 136 participants, but its current recruitment status is unclear.

Study design
This interventional study plans to enroll 136 healthy participants. It will involve giving participants BMS-986533, Famotidine, Placebo, Dabigatran Etexilate, or Rosuvastatin.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for adverse events for up to 47 days and for vital sign abnormalities for up to 27 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07629999

Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

Recruiting
PHASE1Ages 18–55InterventionalTreatment
Bristol-Myers Squibb
~136 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:BMS-986533FamotidinePlaceboDabigatran EtexilateRosuvastatin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with Adverse Events (AE)
Measured over Up to Day 47
+6 more outcomes measured

Conditions

Healthy Volunteers

Explore related trials

Healthy Volunteers

NCT07629999

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Celerion Coorporate Office Nebraska

    Lincoln, Nebraskano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have a body mass index (BMI) of 18 to 32.44 kg/m2, inclusive, and total body weight ≥ 50 kg.
Female (as assigned at birth) participants who are not of childbearing potential must have documented proof of reproductive status.
A male (as assigned at birth) who is sexually active with IOCBP must agree to follow instructions for method(s) of contraception as described and included in the ICF.

Exclusion

Participants must not have presence or history of any clinically relevant abnormality, condition, or disease of renal, hepatic, hematologic, GI, endocrine, pulmonary, neurologic, or immunologic (including history of angioedema or hypersensitivity reactions to medication).
Participants must not have current or recent (within 3 months of study intervention administration) clinically significant GI disease.
Participants must not have any major surgery within 3 months of study intervention administration.
Participants must not have Any surgical or medical intervention that could possibly affect ADME of study intervention (eg, bariatric surgery, GI surgery).

What this trial measures

  • Number of participants with Adverse Events (AE)Up to Day 47
  • Number of participants with Serious Adverse Events (SAE)Up to Day 47
  • Number of participants with Vital Sign AbnormalitiesUp to Day 27
  • Number of participants with Physical Examination AbnormalitiesUp to Day 27

    Including neurological examination

  • Number of participants with Electrocardiogram (ECG) AbnormalitiesUp to Day 27
  • Number of participants with Clinical Laboratory Assessments AbnormalitiesUp to Day 27
  • Number of participants with Treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)Up to Day 27